PMID- 35798286
OWN - NLM
STAT- MEDLINE
DCOM- 20220809
LR  - 20220818
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 182
DP  - 2022 Aug
TI  - A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for 
      cancer immunotherapy.
PG  - 106343
LID - S1043-6618(22)00288-2 [pii]
LID - 10.1016/j.phrs.2022.106343 [doi]
AB  - Although the blockade of immune checkpoint PD-1/PD-L1 has achieved great success, 
      the lack of tumor-infiltrating immune cells and PD-L1 expression in the tumor 
      microenvironment results in a limited response in certain tumor types. Thus, 
      rational and optimal combination strategies were urgently needed. The combination 
      of PD-1/PD-L1 blockade and anti-angiogenic therapy has been reported to have 
      great potential. Here, a chimeric peptide OGS was designed by conjugating the 
      peptides OPBP-1 (8-12) and (D)A7R targeting PD-L1 and VEGFR2, respectively. OGS 
      could bind to both human and mouse PD-L1 with high affinity and block the 
      PD-1/PD-L1 interaction, and also inhibit the migration and tube formation of 
      HUVEC cells in wound healing and tube formation assays. To further prolong the 
      half-life of OGS, it was modified by coupling with peptide (D)SP which has a high 
      binding affinity to both human serum albumin (HSA) and mouse serum albumin (MSA) 
      to form the peptide (D)SPOGS. (D)SPOGS could not directly affect the viability, 
      apoptosis, and cell cycle of tumor cells in vitro, while significantly inhibiting 
      the tumor growth in the MC38 mouse model. (D)SPOGS could elicit a potent 
      anti-tumor immune response and inhibit tumor angiogenesis, with the enhancement 
      of tumor infiltrating CD8(+) T cells and the IFN-gamma secreting CD8(+) T cells in 
      the spleen and tumor-draining lymph node. Further, the combination of 
      radiotherapy with (D)SPOGS could dramatically improve the therapeutic efficacy. 
      Our study could provide a promising paradigm for the combination of immune 
      checkpoint blockade, anti-angiogenesis, and radiotherapy.
CI  - Copyright (c) 2022 Elsevier Ltd. All rights reserved.
FAU - Jiao, Ling
AU  - Jiao L
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.
FAU - Dong, Qingyu
AU  - Dong Q
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.
FAU - Zhai, Wenjie
AU  - Zhai W
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.
FAU - Zhao, Wenshan
AU  - Zhao W
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.
FAU - Shi, Peishang
AU  - Shi P
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.
FAU - Wu, Yahong
AU  - Wu Y
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.
FAU - Zhou, Xiuman
AU  - Zhou X
AD  - School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen 
      518107, China. Electronic address: zhouxm36@mail.sysu.edu.cn.
FAU - Gao, Yanfeng
AU  - Gao Y
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China; School of 
      Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen 518107, 
      China. Electronic address: gaoyf29@mail.sysu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220704
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Peptides)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - EC 2.7.10.1 (KDR protein, human)
RN  - EC 2.7.10.1 (Kdr protein, mouse)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
SB  - IM
MH  - Animals
MH  - *B7-H1 Antigen/metabolism
MH  - CD8-Positive T-Lymphocytes
MH  - Cell Line, Tumor
MH  - Humans
MH  - Immunotherapy/methods
MH  - Mice
MH  - *Neoplasms/drug therapy/radiotherapy
MH  - Peptides/pharmacology/therapeutic use
MH  - Programmed Cell Death 1 Receptor/metabolism
MH  - Tumor Microenvironment
MH  - Vascular Endothelial Growth Factor Receptor-2/*metabolism
OTO - NOTNLM
OT  - Albumin binding peptide
OT  - Angiogenesis
OT  - Cancer immunotherapy
OT  - PD-1/PD-L1
OT  - Radiotherapy
EDAT- 2022/07/08 06:00
MHDA- 2022/08/10 06:00
CRDT- 2022/07/07 19:33
PHST- 2022/01/08 00:00 [received]
PHST- 2022/06/03 00:00 [revised]
PHST- 2022/07/01 00:00 [accepted]
PHST- 2022/07/08 06:00 [pubmed]
PHST- 2022/08/10 06:00 [medline]
PHST- 2022/07/07 19:33 [entrez]
AID - S1043-6618(22)00288-2 [pii]
AID - 10.1016/j.phrs.2022.106343 [doi]
PST - ppublish
SO  - Pharmacol Res. 2022 Aug;182:106343. doi: 10.1016/j.phrs.2022.106343. Epub 2022 
      Jul 4.